IO Biotech welcomes David Smith to its Board of Directors

– DENMARK, Copenhagen –  IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company today announced the appointment of David Smith to its Board of Directors.

“David is a welcome addition to the IO Biotech Board, bringing substantial experience in guiding multiple biotech companies through all stages of development as well as deep expertise in finance and corporate governance. We are fortunate to have someone of David’s caliber join us as we pursue our passion to serve cancer patients,” said founder and CEO, Dr. Mai-Britt Zocca.

Mr. Smith will also join the Audit Committee.

About David V. Smith

Mr. Smith most recently served as EVP and CFO at Five Prime Therapeutics, a publicly-traded company focused on discovering and developing novel immuno-oncology protein therapeutics, acquired by Amgen in April 2021. Previously, Mr. Smith served as COO of IntegenX and CFO of Thoratec, Chiron, and Anergen, Inc. He has also held finance positions with Genentech, Inc., Syntex, and IBM. Mr. Smith is currently the Chair of the Audit and Strategy Committees of Codexis, Inc., the Chair of the Audit Committee of Neurelis, Inc., and a Director of Acepodia, Inc. Previously, he served as chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc., and Perlegen Sciences, Inc.

“I am delighted to join the Board at this exciting time in IO Biotech’s evolution,” commented David Smith. “With compelling data, a promising late-stage pipeline of immune-modulating cancer therapies based on its T-win® platform, and a solid balance sheet, the Company is well-positioned to execute on its mission and advance its programs towards data readouts.”

Mr. Smith holds a BA in economics and history from Willamette University and an MBA in finance from Golden Gate University.

About IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform. The T-win platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark, and has additional offices within the United States (New York, New York, and Rockville, Maryland) and United Kingdom (Monmouthshire).

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team